Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy strategies in metastatic hormone-sensitive prostate cancer (multi-arm, multi-stage randomized phase II/III)
2017-004377-13Phase 2Completed
- Sponsor
- SOGUG
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in prostate cancer (PCa) comparing Standard of care (ADT + chemotherapy), Standard of care + ipilimumab and Standard of care + nivolumab (3 arms). Primary endpoint: Overall Survival. Started Oct 2018; status: completed.
02
Drugs
ipilimumabnivolumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2017-004377-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004377-13.